Orphan designation: Zanidatamab, Treatment of gastric cancer, 13/11/2020, Positive
On 13 November 2020, orphan designation EU/3/20/2353 was granted by the European Commission to Voisin Consulting S.A.R.L., France, for zanidatamab (also known as ZW25) for the treatment of gastric cancer.
In October 2021, Voisin Consulting S.A.R.L. changed name to Voisin Consulting Life Sciences.
The sponsorship was transferred from Voisin Consulting Life Sciences, France, to Jazz Pharmaceuticals Ireland Limited, Ireland in June 2023.
Legal Disclaimer:
EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.
